Abstract:Elaborate regulation of innate immunity is necessary for the host to effectively respond to invading pathogens. As an important component of antiviral immunity transcription factors, the stability and activity of interferon (IFN) regulatory factor 3 (IRF3) are tightly controlled via multiple post-translational modifications. Here, we identified a human ovarian tumor domain-containing deubiquitinase OTUD6B as a positive regulator of IRF3 that facilitates type I IFN innate antiviral immune signaling. Mechanically, we found that OTUD6B interacts with IRF3 and directly hydrolyzes both the lysine 11 (K11)- and the lysine 33 (K33)-linked polyubiquitin chain, but only K33-linked polyubiquitin at Lys315 of IRF3 is responsible for IRF3 proteasome degradation. Notably, OTUD6B enhanced cellular antiviral responses in vivo, as evidenced by mice that overexpressed human OTUD6B were more resistant to RNA virus infection and had reduced viral load and morbidity. These findings revealed a previously unknown role for OTUD6B in the regulation of innate antiviral immunity and may provide a potential target for enhancing host antiviral defense.IMPORTANCE Interferon (IFN) regulatory factor (IRF3) is one of the key factors for type I IFN transcription. To sophisticatedly regulate type I IFN antiviral immune response, IRF3 activity is closely controlled by a variety of post-translational modifications. However, the regulatory mechanisms are still not fully elucidated. In the present study, we found that human deubiquitinase OTUD6B positively regulates IRF3-mediated antiviral immune response. OTUD6B can stabilize the IRF3 protein level via hydrolyzing (Lys33)-linked polyubiquitin at Lys315. More importantly, mice with OTUD6B overexpression exhibited more resistance to RNA virus infection. Thus, unlike the previous report that zebrafish OTUD6B negatively regulates the antiviral response by suppressing K63-linked ubiquitination of IRF3 and IRF7, we demonstrate that human OTUD6B actually enhances type I IFN response and has the potential for antiviral therapy.

OTUD1 Negatively Regulates Type I IFN Induction by Disrupting Noncanonical Ubiquitination of IRF3

NBR1 Mediates Autophagic Degradation of IRF3 to Negatively Regulate Type I Interferon Production.

OTUD7B controls non-canonical NF-κB activation through deubiquitination of TRAF3

Human OTUD6B Positively Regulates Type I IFN Antiviral Innate Immune Responses by Deubiquitinating and Stabilizing IRF3.

Otud7b facilitates T cell activation and inflammatory responses by regulating Zap70 ubiquitination

Ste20-Like Kinase TAOK1 Positively Regulates Antiviral Responses by Controlling the TBK1-IRF3 Signaling Axis

Induction of OTUD1 by RNA viruses potently inhibits innate immune responses by promoting degradation of the MAVS/TRAF3/TRAF6 signalosome.

OTUD7B deubiquitinates SQSTM1/p62 and promotes IRF3 degradation to regulate antiviral immunity

Acetylation-Dependent Deubiquitinase OTUD3 Controls MAVS Activation in Innate Antiviral Immunity

Deubiquitination of proteasome subunits by OTULIN regulates type I IFN production

Selective autophagy controls the stability of transcription factor IRF3 to balance type I interferon production and immune suppression

Mst1 shuts off cytosolic antiviral defense through IRF3 phosphorylation.

Forkhead box O1-mediated ubiquitination suppresses RIG-I-mediated antiviral immune responses

Deubiquitinase OTUD6A Regulates Innate Immune Response Via Targeting UBC13

Deubiquitinase USP47 attenuates virus-induced type I interferon signaling

TOB1 attenuates IRF3-directed antiviral responses by recruiting HDAC8 to specifically suppress IFN-β expression

Opposing effects of deubiquitinase OTUD3 in innate immunity against RNA and DNA viruses

Mutations of deubiquitinase OTUD1 are associated with autoimmune disorders

A Novel Transcript Isoform of TBK1 Negatively Regulates Type I IFN Production by Promoting Proteasomal Degradation of TBK1 and Lysosomal Degradation of IRF3

Negative feedback regulation of cellular antiviral signaling by RBCK1-mediated degradation of IRF3

USP3 Inhibits Type I Interferon Signaling by Deubiquitinating RIG-I-like Receptors